



PRODUCT: **TAKHZYRO® (lanadelumab-flyo)**

COMPANY:

Takeda Pharmaceutical Company Limited

THERAPEUTIC AREA & INDICATION:

Treatment for hereditary angioedema (HAE)
in adults

ABOUT THE PRODUCT

TAKHZYRO (lanadelumab-flyo) is a subcutaneous injection indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients 12 years of age and older. HAE is a rare and potentially life-threatening genetic disorder that causes painful and sudden swelling in any part of the body, including hands, feet, face, abdomen, and throat. HAE attacks are unpredictable, and the frequency or severity of previous attacks are not predictors of future attacks. TAKHZYRO, a monoclonal antibody that targets inhibition of plasma kallikrein, has been proven to reduce the frequency and severity of attacks.